Literature DB >> 7349335

Xylazine-induced mydriasis: possible involvement of a central postsynaptic regulation of parasympathetic tone.

W H Hsu, D M Betts, P Lee.   

Abstract

Intravenous injection of xylazine (0.01-1 mg/kg) produced a dose-dependent mydriasis associated with a depression of tonic ciliary nerve activity in anesthetized cats. Xylazine-induced mydriasis was apparent in the sympathectomized iris but was absent in the parasympathectomized, physostigmine-treated iris. Epinephrine (30 micrograms/kg, i.v.) produced a slightly greater mydriasis in the sympathectomized iris than in the parasympathectomized, physostigmine-treated iris. The alpha 2-adrenergic blocking agent, yohimbine (0.5 mg/kg, i.v.) antagonized the pupillary dilation and reversed the depression of ciliary nerve activity induced by xylazine administration. In rats pretreated with reserpine (7.5 mg/kg, s.c., 20 h) and alpha-methyl-p-tyrosine (250 mg/kg, i.p., 5 h), intravenous injection of xylazine (0.01-1 mg/kg) resulted in mydriasis of similar magnitude as control animals. However, xylazine induced bradycardia in the control group but not in the pretreated animals. The results suggest that pupillary dilation produced by i.v. xylazine is primarily the result of a central inhibition of parasympathetic tone to the iris. It also appears that xylazine produces this effect via postsynaptic alpha 2-adrenergic mechanisms, while it produces bradycardia through a presynaptic alpha 2-adrenergic mechanism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7349335     DOI: 10.1111/j.1365-2885.1981.tb00731.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

1.  Ketamine-xylazine anesthesia causes hyperopic refractive shift in mice.

Authors:  Tatiana V Tkatchenko; Andrei V Tkatchenko
Journal:  J Neurosci Methods       Date:  2010-09-08       Impact factor: 2.390

2.  Analysis of the Ocular Refractive State in Fighting Bulls: Astigmatism Prevalence.

Authors:  Juan M Bueno; Matteo Lo Sapio; J Manuel Sanes; Juan Seva
Journal:  Biomed Res Int       Date:  2017-11-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.